AbbVie reported second quarter net revenues of $16.99 billion, an increase of 10.2% year-over-year, while adjusted diluted EPS was $3.65, a 22.9% increase from the prior year. The results were driven by continued growth in the immunology and neuroscience portfolios, which offset the ongoing decline of Humira.
Key Highlights
- Global immunology portfolio revenue grew 15.1% to $8.79 billion, driven by Skyrizi sales of $5.51 billion (+24.4%) and Rinvoq sales of $2.53 billion (+24.5%).
- The neuroscience portfolio delivered strong growth, with revenues increasing 20.3% to $3.23 billion, led by Vraylar ($1.07 billion) and Botox Therapeutic ($1.04 billion).
- AbbVie updated its full-year 2026 adjusted diluted EPS guidance to $13.87 - $14.07, down from $13.91 - $14.11, primarily to reflect the dilutive impact of the proposed Apogee Therapeutics acquisition.